Exploration of the chemical space of benzamide-based voltage-gated potassium channel Kv1.3 inhibitors
References
- G. Yellen, The voltage-gated potassium channels and their relatives, Nature 419(6902) (2002) 35–42; https://doi.org/10.1038/nature00978
- A. Serrano-Albarrás, I. Estadella, S. Cirera-Rocosa, M. Navarro-Pérez and A. Felipe, Kv1.3: A multi-functional channel with many pathological implications, Expert Opin. Ther. Targets 22(2) (2018) 101–105; https://doi.org/10.1080/14728222.2017.1420170
- M. T. Pérez-García, P. Cidad and J. R. López-López, The secret life of ion channels: Kv1.3 potassium channels and proliferation, Am. J. Physiol.-Cell Physiol. 314(1) (2018) C27–C42; https://doi.org/10.1152/ajpcell.00136.2017
- H. Wulff and M. Pennington, Targeting effector memory t-cells with Kv1.3 blockers, Curr. Opin. Drug Discov. Devel. 10(4) (2007) 438–445.
- K. G. Chandy and R. S. Norton, Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease, Curr. Opin. Chem. Biol. 38 (2017) 97–107; https://doi.org/10.1016/j.cbpa.2017.02.015
- N. Comes, A. Serrano-Albarrás, J. Capera, C. Serrano-Novillo, E. Condom, S. Ramón Y Cajal, J. C. Ferreres and A. Felipe, Involvement of potassium channels in the progression of cancer to a more malignant phenotype, Biochim. Biophys. Acta BBA - Biomembr. 1848(10) (2015) 2477–2492; https://doi.org/10.1016/j.bbamem.2014.12.008
- N. Comes, J. Bielanska, A. Vallejo-Gracia, A. Serrano-Albarrás, L. Marruecos, D. Gómez, C. Soler, E. Condom, S. Ramón Y Cajal, J. Hernández-Losa, J. C. Ferreres and A. Felipe, The voltage-dependent K+ channels Kv1.3 and Kv1.5 in human cancer, Front. Physiol. 4 (2013) Article ID 283 (13 pages); https://doi.org/10.3389/fphys.2013.00283
- C. Serrano-Novillo, J. Capera, M. Colomer-Molera, E. Condom, J. Ferreres and A. Felipe, Implication of voltage-gated potassium channels in neoplastic cell proliferation, Cancers 11(3) (2019) Article ID 287 (17 pages); https://doi.org/10.3390/cancers11030287
- A. Teisseyre, J. Gąsiorowska and K. Michalak, Voltage-gated potassium channels Kv1.3 – poten-tially new molecular target in cancer diagnostics and therapy, Adv. Clin. Exp. Med. 24(3) (2015) 517–524; https://doi.org/10.17219/acem/22339
- M. Pérez-Verdaguer, J. Capera, C. Serrano-Novillo, I. Estadella, D. Sastre and A. Felipe, The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies, Expert Opin. Ther. Targets 20(5) (2016) 577–591; https://doi.org/10.1517/14728222.2016.1112792
- A. Schmitz, A. Sankaranarayanan, P. Azam, K. Schmidt-Lassen, D. Homerick, W. Hänsel and H. Wulff, Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases, Mol. Pharmacol. 68(5) (2005) 1254–1270; https://doi.org/10.1124/mol.105.015669
- Y. R. Ren, F. Pan, S. Parvez, A. Fleig, C. R. Chong, J. Xu, Y. Dang, J. Zhang, H. Jiang, R. Penner and J. O. Liu, Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes, PLoS one 3(12) (2008) e4009 (11 pages); https://doi.org/10.1371/journal.pone.0004009
- W. A. Schmalhofer, J. Bao, O. B. McManus, B. Green, M. Matyskiela, D. Wunderler, R. M. Bugianesi, J. P. Felix, M. Hanner, A.-R. Linde-Arias, C. G. Ponte, L. Velasco, G. Koo, M. J. Staruch, S. Miao, W. H. Parsons, K. Rupprecht, R. S. Slaughter, G. J. Kaczorowski and M. L. Garcia, Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant proper-ties, Biochemistry 41(24) (2002) 7781–7794; https://doi.org/10.1021/bi025722c
- L. A. Hendrickx, V. Dobričić, Ž. Toplak, S. Peigneur, L. P. Mašič, T. Tomašič and J. Tytgat, Design and characterization of a novel structural class of Kv1.3 inhibitors, Bioorg. Chem. 98 (2020) Article ID 103746 (9 pages). https://doi.org/10.1016/j.bioorg.2020.103746
- Š. Gubič, L. A. Hendrickx, X. Shi, Ž. Toplak, Š. Možina, K. M. V. Theemsche, E. L. Pinheiro-Junior, S. Peigneur, A. J. Labro, L. A. Pardo, J. Tytgat, T. Tomašič and L. P. Mašič, Design of new potent and selective thiophene-based KV1.3 inhibitors and their potential for anticancer activity, Cancers 14(11) (2022) Article ID 2595 (20 pages); https://doi.org/10.3390/cancers14112595
- Š. Gubič, A. Montalbano, C. Sala, A. Becchetti, L. A. Hendrickx, K. M. Van Theemsche, E. L. Pinheiro-Junior, G. C. Altadonna, S. Peigneur, J. Ilaš, A. J. Labro, L. A. Pardo, J. Tytgat, T. Tomašič, A. Arcangeli and L. Peterlin Mašič, Immunosuppressive effects of new thiophene-based KV1.3 inhibitors, Eur. J. Med. Chem. 259 (2023) Article ID 115561 (17 pages); https://doi.org/10.1016/j.ejmech.2023.115561
Language: English
Page range: 219 - 233
Accepted on: May 30, 2025
Published on: Jul 3, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2025 Marzia Fois, Špela Pelcar, Joshua A. Nasburg, Heike Wulff, Lucija Peterlin Mašič, Tihomir Tomašič, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.